Edwards Lifesciences Corporation (NYSE:EW) Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. lowered its stake in Edwards Lifesciences Corporation (NYSE:EW) by 81.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,662 shares of the medical research company’s stock after selling 29,763 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Edwards Lifesciences were worth $483,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Allspring Global Investments Holdings LLC lifted its holdings in Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after acquiring an additional 145 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $49,038,000. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock worth $5,582,000 after buying an additional 9,188 shares during the period. Dynamic Advisor Solutions LLC boosted its holdings in shares of Edwards Lifesciences by 2.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company’s stock worth $1,124,000 after buying an additional 370 shares during the period. Finally, Advanced Portfolio Management LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $328,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on EW shares. Wells Fargo & Company raised their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Stifel Nicolaus raised their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, July 25th. Wall Street Zen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Finally, BTIG Research upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Tuesday, July 29th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.90.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $77.69 on Thursday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00. The stock’s 50 day moving average is $77.10 and its 200-day moving average is $74.29. The firm has a market capitalization of $45.61 billion, a price-to-earnings ratio of 11.18, a PEG ratio of 3.71 and a beta of 1.08.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 11.9% on a year-over-year basis. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the transaction, the vice president owned 50,356 shares of the company’s stock, valued at $3,897,554.40. The trade was a 4.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,134 shares of company stock worth $1,311,745 over the last 90 days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.